94 related articles for article (PubMed ID: 14763143)
21. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Forastiere AA; Burtness BA
J Clin Oncol; 2007 Jun; 25(16):2152-5. PubMed ID: 17538157
[No Abstract] [Full Text] [Related]
22. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
23. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
24. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Cohen RB
Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
[TBL] [Abstract][Full Text] [Related]
26. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
28. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
29. HER-targeted tyrosine-kinase inhibitors.
Baselga J; Hammond LA
Oncology; 2002; 63 Suppl 1():6-16. PubMed ID: 12422050
[TBL] [Abstract][Full Text] [Related]
30. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
31. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
[TBL] [Abstract][Full Text] [Related]
32. [Lung cancer: molecular targeting therapy].
Kobayashi K
Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):371-7. PubMed ID: 15168452
[No Abstract] [Full Text] [Related]
33. [Inhibitors of epidermal growth factor receptor and colorectal cancer].
Adenis A; Peyrat JP
Bull Cancer; 2003 Nov; 90 Spec No():S228-32. PubMed ID: 14763144
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor targeted therapies for solid tumours.
Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
[TBL] [Abstract][Full Text] [Related]
35. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
Dancey JE; Schoenfeldt M
Oncology (Williston Park); 2001 Jun; 15(6):748-50, 756-8. PubMed ID: 11430207
[No Abstract] [Full Text] [Related]
37. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
38. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor inhibitors in clinical development.
Dancey J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):1003-7. PubMed ID: 14967462
[TBL] [Abstract][Full Text] [Related]
40. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
